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Ovarian stimulation for IVF and risk of primary breast cancer
in BRCA1/2 mutation carriers
Inge A. P. Derks-Smeets1,2, Lieske H. Schrijver3, Christine E. M. de Die-Smulders1,2, Vivianne C. G. Tjan-Heijnen2,4, Ron J. T. van Golde2,5,
Luc J. Smits6, Beppy Caanen1, Christi J. van Asperen7, Margreet Ausems8, Margriet Collée9, Klaartje van Engelen10, C. Marleen Kets11,
Lizet van der Kolk12, Jan C. Oosterwijk13, Theo A. M. van Os14, HEBON, Matti A. Rookus3, Flora E. van Leeuwen3 and
Encarna B. Gómez García1,2
BACKGROUND: The effect of in vitro fertilisation (IVF) on breast cancer risk for BRCA1/2 mutation carriers is rarely examined. As
carriers may increasingly undergo IVF as part of preimplantation genetic diagnosis (PGD), we examined the impact of ovarian
stimulation for IVF on breast cancer risk in BRCA1/2 mutation carriers.
METHODS: The study population consisted of 1550 BRCA1 and 964 BRCA2 mutation carriers, derived from the nationwide HEBON
study and the nationwide PGD registry. Questionnaires, clinical records and linkages with the Netherlands Cancer Registry were
used to collect data on IVF exposure, risk-reducing surgeries and cancer diagnosis, respectively. Time-dependent Cox regression
analyses were conducted, stratiﬁed for birth cohort and adjusted for subfertility.
RESULTS: Of the 2514 BRCA1/2 mutation carriers, 3% (n= 76) were exposed to ovarian stimulation for IVF. In total, 938 BRCA1/2
mutation carriers (37.3%) were diagnosed with breast cancer. IVF exposure was not associated with risk of breast cancer (HR: 0.79,
95% CI: 0.46–1.36). Similar results were found for the subgroups of subfertile women (n= 232; HR: 0.73, 95% CI: 0.39–1.37) and
BRCA1 mutation carriers (HR: 1.12, 95% CI: 0.60–2.09). In addition, age at and recency of ﬁrst IVF treatment were not associated with
breast cancer risk.
CONCLUSION: No evidence was found for an association between ovarian stimulation for IVF and breast cancer risk in BRCA1/2
mutation carriers.
British Journal of Cancer (2018) 119:357–363; https://doi.org/10.1038/s41416-018-0139-1
INTRODUCTION
Women with a mutation in the BRCA1 or BRCA2 gene have an
increased risk of breast, ovarian and other types of cancer.1,2 Both
exogenous and endogenous oestrogens and progestogens have
been shown to affect breast cancer risk in both the general
population and mutation carriers.3–7 In vitro fertilisation (IVF) might
inﬂuence breast cancer risk, as the use of a long agonist protocol
for ovarian stimulation for IVF results in a period of decreased
levels of oestrogen and progesterone due to downregulation of
the natural hormonal cycle,8 followed by a temporary hyperoes-
trogenic state.9 Hypothetically, this hyperoestrogenic environment
might be carcinogenic, as are prolonged cyclic changes in
oestrogen and progesterone levels. For BRCA1/2 mutation carriers
not only infertility, but also oncologic treatment strategies affecting
fertility and/or risk-reducing salpingo-oophorectomy direct female
mutation carriers to ovarian stimulation for IVF for fertility
preservation.10,11 In addition, during the past decade the request
for preimplantation genetic diagnosis (PGD) has increased rapidly
for BRCA1/2 mutation carriers, i.e., genetic testing of embryos for
the presence of a known familial mutation before transfer in order
to establish a pregnancy of a foetus without the genetic
condition.12–14
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In the general population, recent meta-analyses did not report
an association between exposure to ovarian stimulation for IVF
and breast cancer risk.15,16 A large recent cohort study in over
19,000 Dutch women did also not show an adverse effect of IVF
on breast cancer risk.17
For women with a BRCA1/2 mutation the association between
exposure to ovarian stimulation for IVF and breast cancer risk has
hardly been studied. The only case–control study conducted did
not ﬁnd an elevated risk of breast cancer associated with IVF
exposure.18 As women with BRCA1/2 mutations have a high a
priori absolute risk of breast cancer development already at early,
reproductive ages (cumulative risks of 20% by age 38 and 43 apply
for BRCA1 and BRCA2, respectively,1 even a small adverse effect of
ovarian stimulation for IVF could have substantial impact. This is all
the more important given the high prevalence of heterozygous
BRCA1/2 germline mutations (i.e., 1:400 up to 1:200 persons in
some general populations19 and 1:40 in certain ethnic groups.20
The aim of the current study is to evaluate whether exposure to
ovarian stimulation for IVF increases the risk of primary breast
cancer in BRCA1 and BRCA2 mutation carriers.
PATIENTS AND METHODS
Women were eligible if they were 18 years or older and had been
tested positive for a pathogenic mutation in either the BRCA1 or
BRCA2 gene. Women born before 1940 were excluded because
they had their reproductive years before IVF was available.
Our study population was derived from two sources: the Dutch
HEBON study (Hereditary Breast and Ovarian cancer study, the
Netherlands) and the national PGD registry.
The HEBON study (initiated in 1999) is an ongoing nationwide
retrospective cohort study among members of BRCA1/2 mutation
families with prospective follow-up.21 Participants were invited
into the study after they became aware of their mutation carrier
status through a clinical genetic test. Current analyses were
restricted to participants that entered the HEBON cohort between
2010 and 2013, since only the most recent HEBON baseline
questionnaire included questions concerning exposure to fertility
treatments; response to the most recent HEBON questionnaire
was 57%. In the Netherlands, PGD for BRCA1/2mutations has been
offered since 2008 in Maastricht University Medical Centre, in
collaboration with IVF transport clinics in University Medical
Centres of Utrecht and Groningen, and the Academic Medical
Centre Amsterdam. All women who undergo PGD are registered in
the PGD registry. Some women were eligible through the HEBON
study and had also been registered in the PGD registry.
The HEBON study was approved by the medical ethics
committees of all participating Dutch University Medical Centres
or Family Cancer Clinics. All HEBON participants gave their informed
consent for linkage with the nationwide cancer and pathology
registries. The PGD programme has been approved by the
Institutional Review Board of Maastricht University Medical Centre.
All patients undergoing PGD gave their written informed consent for
this treatment and use of their medical data for scientiﬁc research.
Data collection
For BRCA1/2 mutation carriers included through the HEBON study,
data on exposure to IVF and other fertility treatments (i.e.,
ovulation induction and intra-uterine insemination), prophylactic
surgeries and confounders were collected with the HEBON
baseline questionnaire. In case of female subfertility (deﬁned as
the inability to establish a clinical pregnancy within 12 or more
months of regular, unprotected sexual intercourse with the
intention to conceive), women reported the type(s) of fertility
treatment(s) they underwent and their age at ﬁrst and last
treatment. Information on cancer history was self-reported but
also obtained by linkage with both the Dutch national Pathology
Database (PALGA) and the Netherlands Cancer Registry (NCR) for
the period after 1988. For the period when these registries were
not yet available (≤1988), cancer diagnoses were solely self-
reported. For the women included through the PGD registry, data
on exposure (type of fertility treatment(s) and age at treatments),
potential confounders, prophylactic surgeries and cancer history
were retrieved from medical ﬁles.
For women eligible through the HEBON study and also registered
in the PGD registry, the data from medical ﬁles and the HEBON
questionnaire were combined. No conﬂicting data were found.
Statistical analysis
The association between IVF exposure and risk of breast cancer
was analysed using a time-dependent Cox proportional hazards
regression model with age as the timescale. Main analyses were
stratiﬁed for birth cohort (based on tertiles of number of carriers
per category: 1940–1957, 1958–1968 and 1969–1993) and
adjusted for subfertility (no, yes or missing). Observation time
started at birth and ended at age at diagnosis of ﬁrst invasive
breast cancer (event of interest), other invasive cancer diagnosis
(excl. basal cell carcinoma) or bilateral prophylactic mastectomy
(BPM), whichever occurred ﬁrst. In case these events did not take
place before baseline questionnaire or last PGD contact, observa-
tion time ended at the age of baseline questionnaire completion
or last PGD contact, whichever was last.
The exposed group, in terms of person-time, consisted of
observation time of BRCA1/2 mutation carriers who had under-
gone ovarian stimulation for IVF before censoring. Women were
considered as exposed to IVF from the ﬁrst IVF treatment onward.
The unexposed (comparison) person-time consisted of observa-
tion time of BRCA1/2 mutation carriers who had not (yet) been
exposed to ovarian stimulation for IVF before censoring. Cutoffs of
categories in variables related to IVF characteristics are based on
number of cases available in the exposed group.
Potential confounders, besides subfertility and birth cohort,
were exposure to other fertility treatments (clomid and/or intra-
uterine insemination (in which hormonal treatment may be
included)), (time-dependent: ever/never), use of oral contracep-
tives (time-dependent: ever/never), parity (time-dependent: nulli-
parous/parous) and age at ﬁrst childbirth (time-dependent:
nulliparous/<25 years/25–29 years/30+ years). None of these
changed the hazard ratio (HR) for IVF treatment by more than 10%
and therefore they were not included. The uptake of an RRSO
could only be tested as a potential confounder in an unbiased
manner by comparing univariate and multivariate analyses from
analyses between IVF uptake and breast cancer risk with restricted
follow-up time until age at DNA test, since the uptake of RRSO
mainly depends on the outcome of the DNA test.22 As univariate
and multivariate HRs were similar (<10% change), RRSO uptake
was not considered to be a confounder.
BRCA mutation-speciﬁc analyses were only conducted in the
subgroup of BRCA1mutation carriers since power in BRCA2 carriers
was too limited. An additional sensitivity analysis restricted to
subfertile women was conducted to further assess any association
in this stratum.
All statistical analyses were performed using STATA version 13
(StataCorp, College Station, TX).
RESULTS
Patient characteristics
The ﬁnal group eligible for analysis comprised 2514 BRCA1/2
mutation carriers (1550 BRCA1 and 964 BRCA2). Of these, 2502
(99.5%) women participated in the HEBON study. The PGD group
included a total of 25 eligible women, including 13 responders to
the HEBON study (Fig. 1).
In total, 938 of 2514 women (37.3%) were diagnosed with
breast cancer, 630/1550 BRCA1 (40.7%) and 308/964 BRCA2
mutation carriers (32.0%, Table 1). The mean age at breast cancer
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Female BRCA1/2 mutation carriers Female BRCA1/2 mutation carriers
HEBON cohort PGD cohort
Total n = 2614 Total n = 57
Exclusion due to:
- PBM before exposure to
IVF/PGD (n = 23) 
- BC before exposure to
IVF/PGD (n = 9)
Eligible n = 25
Exclusion due to:
- Born <1940 (n = 67)
- Unclear BC status (n = 39)
- BRCA1 and BRCA2 mutation
co-occurrence(n = 6)  
Eligible n = 2502
n IVF exposed = 76
- Hebon cohort only: 51
- PGD cohort only: 12
- Both cohorts:13
o  8 PGD before HEBON
    questionnaire
o  5 PGD after HEBON
    questionnaire
n IVF unexposed = 2434
IVF status missing = 4
Fig. 1 Composition of study groups
Table 1. Cohort characteristics of BRCA1/2 mutations carriers
BRCA1(n= 1550) BRCA2(n= 964) BRCA1/2 combined(n= 2514)
BC+a BC−a BC+a BC−a BC+a BC−a
n (%) 630 (40.7) 920 (59.3) 308 (31.9) 656 (68.1) 938 (37.3) 1576 (62.7)
Data source, n (%)
HEBON 629 (99.8) 913 (99.2) 308 (100) 639 (97.4) 937 (99.9) 1552 (98.5)
HEBON+ PGD:
PGD < HEBON 1 (0.2) 2 (0.2) 0 (0.0) 5 (0.8) 1 (0.1) 7 (0.4)
PGD > HEBON 0 (0.0) 1 (0.1) 0 (0.0) 4 (0.6) 0 (0.0) 5 (0.3)
PGD only 0 (0.0) 4 (0.4) 0 (0.0) 8 (1.2) 0 (0.0) 12 (0.8)
Age at censoring (years) (%)
Mean age at censoring (SD) 40.1 (8.5) 43.1 (11.6) 44.4 (8.9) 44.6 (12.0) 41.5 (8.9) 43.7 (11.8)
<35 176 (27.9) 247 (26.9) 36 (11.7) 149 (22.7) 212 (22.6) 396 (25.1)
35–44 276 (43.8) 259 (28.2) 132 (42.9) 190 (29.0) 408 (43.5) 449 (28.5)
45–64 175 (27.8) 384 (41.7) 139 (45.1) 276 (42.1) 314 (33.5) 660 (41.9)
65+ 3 (0.5) 30 (3.3) 1 (0.3) 41 (6.3) 4 (0.4) 71 (4.5)
Censoring reason
Baseline Q/PGD contact 0 (0.0) 561 (61.0) 0 (0.0) 429 (65.4) 0 (0.0) 990 (62.8)
Breast cancer 630 (100) 0 (0.0) 308 (100) 0 (0.0) 938 (100) 0 (0.0)
Other cancer 0 (0.0) 90 (9.8) 0 (0.0) 73 (11.1) 0 (0.0) 163 (10.3)
BPM 0 (0.0) 269 (29.2) 0 (0.0) 154 (23.5) 0 (0.0) 423 (26.8)
Birth year (%)
1940–1957 244 (38.7) 216 (23.5) 153 (49.7) 191 (29.1) 397 (42.3) 407 (25.8)
1958–1968 231 (36.7) 296 (32.2) 101 (32.8) 189 (28.8) 332 (35.4) 485 (30.8)
1969–1993 155 (24.6) 408 (44.4) 54 (17.5) 276 (42.1) 209 (22.3) 684 (43.4)
IVF (%)
No 616 (97.8) 889 (96.6) 305 (99.0) 624 (95.1) 921 (98.2) 1513 (96.0)
Yes 12 (1.9) 29 (3.2) 3 (1.0) 32 (4.9) 15 (1.6) 61 (3.9)
Missing 2 (0.3) 2 (0.2) 0 (0.0) 0 (0.0) 2 (0.2) 2 (0.1)
BC breast cancer, SD standard deviation, Q questionnaire, IVF in vitro fertilisation, PGD preimplantation genetic diagnosis. aDistribution of variables at the time
of censoring
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diagnosis was 40.1 years for BRCA1 and 44.4 years for BRCA2
mutation carriers. Of the remaining participants, 163 (10.3%) were
censored at the age of another cancer diagnosis, 423 (26.8%) at
the age of BPM and 990 women (26.8%) at the age of the
questionnaire or last PGD contact. Their mean age at censoring
was 43.7 years (BRCA1 43.1 years and BRCA2 44.6 years). Those
women only identiﬁed through the PGD registry were on average
younger at censoring compared to the women included through
the HEBON study (33.0 years versus 43.0 years). Of all mutation
carriers, women unaffected with breast cancer were slightly more
often born in more recent birth years (1969–1993: 43.4% mutation
carriers unaffected with breast cancer versus 22.3% affected with
breast cancer).
In total, 3% (n= 76) of all BRCA1/2 mutation carriers included
were exposed to ovarian stimulation for IVF; 41 BRCA1 and 35
BRCA2 mutation carriers. For 51 mutation carriers, IVF exposure
was identiﬁed through the HEBON study and for 25 through the
PGD registry. Due to the nature of the IVF exposure question in
the HEBON study questionnaire (subfertile women only), data on
IVF exposure of eight mutation carriers were collected through the
PGD registry while they were exposed before date of HEBON
questionnaire. Mutation carriers were on average 31.7 years at ﬁrst
IVF treatment. At censoring, their ﬁrst IVF treatment was on
average 6.5 years ago (Table 2). The year of ﬁrst treatment varied
between 1989 and 2015, while mutation carriers included through
the PGD registry received their ﬁrst IVF treatment in more recent
years (HEBON: 1989–2013, median 2003 and PGD: 2010–2015,
median 2013). Mutation carriers exposed to IVF were more often
subfertile (64.5% versus 7.4%) and nulliparous (36.8% versus
19.3%) compared to unexposed mutation carriers.
Breast cancer risk in relation to IVF
At the end of follow-up, 15 mutation carriers (12 BRCA1 and 3
BRCA2) exposed to ovarian stimulation for IVF had developed
breast cancer. Exposure to ovarian stimulation for IVF was not
associated with the risk of breast cancer (HR: 0.79, 95% CI:
0.46–1.36, Table 2). Also, speciﬁc IVF characteristics, e.g., age at
ﬁrst IVF treatment was not associated with breast cancer risk (no
IVF, HR: 1.0 (reference), ≤32 years HR: 1.13, 95% CI: 0.57–2.20, >32
years HR: 0.54, 95% CI: 0.24–1.24; Table 2).
Overall, results of additional analyses in subgroups of BRCA1
mutation carriers and in subfertile women were similar compared
to results based on the total cohort. Both in BRCA1 mutation
carriers (HR: 1.12, 95% CI: 0.60–2.09; Table 3) and in subfertile
women (HR: 0.73, 95% CI: 0.39–1.37; Table 4), IVF exposure was not
associated with breast cancer risk. However, in BRCA1 mutation
carriers a younger age at ﬁrst IVF treatment seemed to be more
strongly related with breast cancer risk than ﬁrst IVF treatment at
older ages (≤32 years HR: 1.91, 95% CI: 0.88–4.16, >32 years HR:
0.70, 95% CI: 0.28–1.76), but numbers were small.
DISCUSSION
We showed that for BRCA1 and BRCA2 mutation carriers breast
cancer risk was not increased after exposure to ovarian stimulation
for IVF. This was also the case when assessing this risk in
subgroups of subfertile women and BRCA1 mutation carriers
alone.
The association between exposure to ovarian stimulation for IVF
and the incidence of breast cancer in BRCA1/2 mutation carriers
was examined in only one previous study. Kotsopoulos et al.18
studied the risk of breast cancer associated with infertility, fertility
treatment and IVF treatment in a case–control design. They
included 1380 women with a BRCA1 or BRCA2 mutation with a
history of breast cancer (cases) and matched them to 1380 female
BRCA1 or BRCA2 mutation carriers without a history of breast
cancer (controls). No association between exposure to IVF and
breast cancer risk was observed (multivariable odds ratio: 0.98,
95% CI: 0.39–2.45, based on nine cases who received IVF), while a
non-signiﬁcantly increased association was found between
exposure to gonadotropin-containing fertility medication and
breast cancer risk (multivariable odds ratio: 2.32, 95% CI:
0.91–5.95). Data regarding types of fertility treatment and
medication used were self-reported in Kotsopoulos et al. and
information concerning the latter was missing in 27% of the study
subjects. Our data regarding type of fertility treatment was self-
reported as well for the greater part of exposed women, and we
did not collect information regarding the type of medication used.
In the Netherlands, IVF is in the vast majority of cases performed
using gonadotropins for ovarian stimulation. Gonadotropins are
also used but to a lesser extent for ovulation induction, as a
second choice for clomiphene citrate-containing drugs (e.g.,
clomid). In the study by Kotsopoulos et al., it was not described
for which fertility treatments gonadotropin-containing medica-
tions were used, nor which types of medication were used for
ovarian stimulation for IVF. Additionally, no information regarding
Table 2. IVF exposure and breast cancer risk in BRCA1/2 mutation
carriers
BC+a BC−a HR (95% CI)b
n= 2514 938 (37.3) 1576 (62.7)
IVF treatment
No 921 (98.2) 1513 (96.0) 1.00
Yes 15 (1.6) 61 (3.9) 0.79
(0.46–1.36)
Missing 2 (0.2) 2 (0.1)
Year at ﬁrst IVF (years)
Median (min–max) 2000
(1988–2010)
2005
(1985–2015)
Age at ﬁrst IVF (%)
Median (min–max,
years)
30.9 (23–37) 31.9 (24–42)
No IVF 921 (98.2) 1513 (96.0) 1.00
≤32 years 9 (1.0) 36 (2.3) 1.13
(0.57–2.2)
>32 years 6 (0.6) 25 (1.6) 0.54
(0.24–1.24)
Missing 2 (0.2) 2 (0.1)
Time since ﬁrst IVF treatment (%)
No IVF 921 (98.2) 1513 (96.0) 1.00
<5 years ago
started
7 (0.8) 34 (2.2) 0.83
(0.39–1.78)
≥5 years ago
started
8 (0.9) 27 (1.7) 0.75
(0.36–1.56)
Missing 2 (0.2) 2 (0.1)
Time since last IVF treatment (%)
No IVF 921 (98.2) 1513 (96.0) 1.00
<2 years ago
stopped
6 (0.6) 20 (1.3) 0.99
(0.43–2.25)
≥2 years ago
stopped
7 (0.8) 40 (2.5) 0.60
(0.28–1.30)
Age of last
treatment before
censoring unknown
2 (0.2) 1 (0.1)
Missing 2 (0.2) 2 (0.1)
BC breast cancer, HR hazard ratio, CI conﬁdence interval, IVF in vitro
fertilisation. aDistribution of variable at time of censoring. bInstrinsically
stratieﬁed on birth year (1940–1957, 1958–1968, 1969–1993); adjusted for
subfertility (no, yes, missing)
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the indication for fertility treatment was provided. As a
consequence, it is difﬁcult to interpret their apparent different
ﬁndings between exposure to IVF treatment and exposure to
gonadotropin-containing drugs. Only 9 and 15 cases and 11 and
61 controls were exposed to IVF in the study of Kotsopoulos et al.
and our study, respectively. Thus, the power in the present study is
larger but still too limited to exclude a true weak association.
The association between ovarian stimulation for IVF and the risk
of breast cancer has been extensively studied in the non-BRCA
population. In a recently published cohort study in over 19,000
Dutch women, the risk of breast cancer after exposure to ovarian
stimulation for IVF was neither different from the risk of breast
cancer in the general population (standardised incidence ratio
(SIR): 1.01, 95% CI: 0.93–1.09) nor from the risk of breast cancer in a
non-IVF subfertile comparison group (HR: 1.01, 95% CI:
0.86–1.19).17 A recent meta-analysis16 drew the same conclusion:
in a cumulative cohort of over 1.5 million women, no association
was found between ovarian stimulation for IVF and breast cancer
risk in the studies conducted in the entire general population
(relative risk (RR): 0.91, 95% CI: 0.74–1.11), nor in studies restricted
to subfertile women (RR: 1.02, 95% CI: 0.88–1.18).
The role of oestrogens in the pathophysiology of breast cancer
in the general population has only been partly elucidated. The
dissimilarities in risks observed associated with exposure to long-
lasting low levels of oestrogens, as is the case in oral contra-
ceptives use and hormone replacement therapy,4,5 and with
exposure to peak levels of oestrogens during a short period of
time as in IVF are not yet understood. The existence of an
oestrogen-receptor alpha (ERα)-dependent and -independent
pathway has been suggested in breast carcinogenesis.23 The
oestrogen-receptor-independent route consists of the enzymatic
conversion of oestrogens into metabolites that damage the
DNA.24 Since the BRCA1 and BRCA2 gene are involved in DNA
repair, it is possible that the potential detrimental effect of
oestrogens on mammary tissue is aggravated in BRCA1/2mutation
carriers. This hypothesis is supported by the observation that
hormonal factors have an inﬂuence on breast cancer risk in BRCA1
mutation carriers, although effect directions are not consistent
with observations in the general population.25 However, no
associations were found between hormonal factors and breast
cancer risk in BRCA2 mutation carriers and in contrast to
retrospective studies, a more recent study does not show a breast
cancer risk reduction after RRSO in BRCA1/2 mutation carriers.22
Prospective studies are needed to provide more insight into the
aetiology of breast cancer in BRCA1/2 mutation carriers and to
further asses the involvement of hormonal factors in the
pathophysiology.
There are several potential explanations for the lack of an effect
of exposure to ovarian stimulation for IVF and the risk of breast
cancer in our study: (1) there is an effect, but the effect size was
too small to be detected due to limited power or observation time
in the current study, (2) there is no true effect, as (a) ovarian
stimulation for IVF has no inﬂuence on breast tissue carcinogen-
esis in BRCA1/2 mutation carriers or (b) a protective inﬂuence of
temporary low levels of oestrogens and progesterone due to
Table 3. IVF exposure and breast cancer risk in BRCA1 mutation
carriers
BC+a BC−a HR (95% CI)b
n= 1550 630 (40.7) 920 (59.4)
IVF treatment
No 616 (97.8) 889 (96.6) 1.00
Yes 12 (1.9) 29 (3.2) 1.12 (0.60–2.09)
Missing 2 (0.3) 2 (0.2)
Age at ﬁrst IVF (%)c
Median (min–max, years) 31.1
(23–36)
32.3
(24–42)
No IVF 616 (97.8) 889 (96.6) 1.00
≤32 years 7 (1.1) 14 (1.5) 1.91 (0.88–4.16)
>32 years 5 (0.8) 15 (1.6) 0.70 (0.28–1.76)
Missing 2 (0.3) 2 (0.2)
Time since ﬁrst IVF treatment (%)c
No IVF 616 (97.8) 889 (96.6) 1.00
<5 years ago started 6 (1.0) 13 (1.4) 1.15 (0.49–2.66)
≥5 years ago started 6 (1.0) 16 (1.7) 1.10 (0.47–2.56)
Missing 2 (0.3) 2 (0.2)
Time since last IVF treatment (%)c
No IVF 616 (97.8) 889 (96.6) 1.00
<2 years ago stopped 5 (0.8) 7 (0.8) 1.49 (0.60–3.73)
≥2 years ago stopped 5 (0.8) 21 (2.3) 0.84 (0.33–2.10)
Age of last treatment
before censoring unknown
2 (0.3) 1 (0.1)
Missing 2 (0.3) 2 (0.2)
BC breast cancer, HR hazard ratio, CI conﬁdence interval, IVF in vitro
fertilisation. aDistribution of variable at time of censoring. bInstrinsically
stratieﬁed on birth year (1940–1957, 1958–1968, 1969–1993); adjusted for
subfertility (no, yes, missing). cCutoffs of categories in variables related to
IVF characteristics are based on number of cases available in the exposed
group
Table 4. IVF exposure and breast cancer risk in subfertile BRCA1/2
mutation carriers
BC+a BC−a HR (95% CI)b
n= 232 93 (40.1) 139 (59.9)
IVF treatment
No 79 (85.0) 100 (71.9) 1.00
Yes 12 (12.9) 37 (26.6) 0.73 (0.39–1.37)
Missing 2 (2.2) 2 (1.4)
Age at ﬁrst IVF (%)c
Median (min–max, years) 31.9
(24–37)
32.6
(24–41)
No IVF 79 (85.0) 100 (71.9) 1.00
≤32 years 6 (6.5) 17 (12.2) 0.93 (0.40–2.17)
>32 years 6 (6.5) 20 (14.4) 0.60 (0.25–1.41)
Missing 2 (2.2) 2 (1.4)
Time since ﬁrst IVF treatment (%)c
No IVF 79 (85.0) 100 (71.9) 1.00
<5 years ago started 6 (6.5) 11 (7.9) 0.94 (0.40–2.22)
≥5 years ago started 6 (6.5) 26 (18.7) 0.59 (0.25–1.40)
Missing 2 (2.2) 2 (1.4)
Time since last IVF treatment (%)c
No IVF 79 (85.0) 100 (71.9) 1.00
<2 years ago stopped 5 (5.4) 7 (5.0) 1.05 (0.41–2.65)
≥2 years ago stopped 6 (6.5) 29 (20.9) 0.55 (0.23–1.31)
Age of last treatment
before censoring unknown
1 (1.1) 1 (0.7)
Missing 2 (2.2) 2 (1.4)
BC breast cancer, HR hazard ratio, CI conﬁdence interval, IVF in vitro
fertilisation. aDistribution of variable at time of censoring. bInstrinsically
stratieﬁed on birth year (1940–1957, 1958–1968, 1969–1993). cCutoffs of
categories in variables related to IVF characteristics are based on numbers
of cases available in the exposed group
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downregulation of the natural cycle in IVF practice, which directs
the effect size to the null, as suggested by van den Belt-
Dusebout.17
In total, 3% of BRCA1/2 mutation carriers included in the current
study were exposed to IVF. The exposed group consisted of both
women undergoing IVF because of subfertility as well as women
opting for IVF because of PGD. After correction for oversampling
by excluding the women ascertained via the national PGD registry,
2% of the women were exposed to IVF. In the general population,
approximately 1% of all women are exposed to IVF.26 Several
studies have suggested a reduced ovarian reserve in female
carriers of a BRCA1 mutation,27–31 but there is no convincing
evidence for a clinically relevant adverse effect on fecundity.
Our study has several limitations. First, despite the availability of
a nationwide BRCA1 and BRCA2 mutation cohort, questions
regarding fertility treatments were only recently added to the
questionnaire and power was still limited due to the low
proportion of women exposed to IVF. To increase the power we
included exposed carriers that were so far not participating in
HEBON or were exposed to IVF after completion of the HEBON
questionnaire, through a merge of the HEBON cohort with BRCA1/
2 mutation carriers included in the PGD registry. Although, in
absolute numbers this was a very small increase, this addition
increased the IVF-exposed group by 33%. There was a difference
in data collection between the two sources, self-reported in a
questionnaire versus medical records; however, it is very unlikely
that IVF exposure (yes/no) was confounded by recall bias. The
difference in age at censoring between the included groups
HEBON and PGD is accounted for by the age-dependent analysis.
Second, the subgroup of BRCA2mutation carriers was too small for
a separate analysis (only three exposed BRCA2 mutation carriers
were diagnosed with breast cancer). Third, the retrospective study
design may have resulted in survival bias if IVF-exposed women
developed tumours with worse prognosis. Although the interval
between breast cancer diagnosis and age at questionnaire was
somewhat lower in IVF-exposed women compared to IVF-
unexposed women (7.1 years ± 5.5 years versus 10.5 ± 8.0,
respectively), this difference was not statistically signiﬁcant (p=
0.052). Fourth, since data were self-reported-speciﬁc information
on IVF protocols used was missing. In addition, in the
questionnaire women were only asked to ﬁll in their IVF history
if they were subfertile. However, since fertile women with a PGD
indication for IVF treatment were included by the PGD registry,
only women opting for IVF treatment because of male subfertility
have possibly been missed, which was the case in 22.3% of the
population of IVF-exposed women.17 Lastly, in our retrospective
cohort approach, breast cancer patients were oversampled due to
the non-random uptake of DNA test. To account for this, a
weighted cohort approach is suggested by Antoniou et al.,32 in
which women with breast cancer and unaffected women are
differentially weighted such that the breast cancer incidence rates
in the study cohort are consistent with age- and birth
cohort–speciﬁc breast cancer risk estimates for BRCA1 and BRCA2
mutation carriers. Unfortunately, power per age group was too
limited to calculate reliable weights.
CONCLUSION AND RECOMMENDATIONS
We did not ﬁnd an increased risk of breast cancer after ovarian
stimulation for IVF in BRCA1/2 mutation carriers. Obviously, ruling
out pre-existing lesions before an IVF treatment is started remains
important, but based on the present knowledge there is no reason
to exclude women with a BRCA1/2 mutation from IVF for fertility
treatment, fertility preservation or PGD. Still, larger studies with a
longer time since IVF treatment are needed to exclude a small
increased breast cancer risk and to investigate the long-term
breast cancer risk for BRCA1/2 mutation carriers.
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